By recent standards, the first quarter of 2024 has been relatively slow in terms of novel drug approvals. Only 10 new drugs were granted authorization in the first three months of the year (Tablel). This compares to 13 in the first quarter of 2023 -a figure that was equalled or best...
17 June 2024 PharmaBoardroom In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China in a single year, write Chunrong Yu of Gracell Biotechnologies and Xu Wang of N...
Table 1 Newly approved drugs grouped by novelty. For definitions, see Introduction. Percentages are those of first-in-indication, first-in-class, and next-in-class drugs with all drugs (included cellular and gene therapies) approved in 2023 taken as 100%. Where available, the International Nonp...
DrugsIn 2023, 2 novel pharmaceutical agents for small animals were released on the German market: the structural but non-functional analog of the inhibitory neurotransmitter gamma-aminobutyric acid pregabalin with an anxiolytic active component and the dopamine agonist ropinirole in form of eye drops ...
We also keep a close eye on reexaminations of the harm-benefit balance of drugs already on the market, news on adverse effects, drug shortages, market withdrawals (instigated by pharmaceutical companies or regulatory authorities), and reintroduction of previously withdrawn drugs.Prescrire international...
New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study.doi:10.1200/JCO.2024.42.16_suppl.35686313568#Background:Postoperative adjuvant chemotherapy for colorectal cancer reduces postoperative recurrence; however, it often causes undesirable adverse events. Oxaliplatin...
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitorsdoi:10.1002/ajh.27248Gangat, NaseemaTefferi, AyalewAmerican Journal of Hematology
The impact of this trend on the accessibility and affordability of newly approved drugs in Europe remains uncertain. The primary objective of this study is to provide insights into the issues of accessibility and affordability of new drugs in the Norwegian healthcare system. ...
DrugsIn 2023, no new active pharmaceutical ingredients were released on the German market for horses and food-producing animals. Two established veterinary active pharmaceutical ingredients became available for additional species: The phosphorus compound butafosfan was also approved for horses, dogs, and...
About Investigational New Drugs The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical...